Diagnosis and treatment of follicular lymphoma.


Autoria(s): Hitz F.; Ketterer N.; Lohri A.; Mey U.; Pederiva S.; Renner C.; Taverna C.; Hartmann A.; Yeow K.; Bodis S.; Zucca E.
Data(s)

2011

Resumo

Follicular lymphoma is a slow-growing disease exhibiting a heterogeneous clinical course, with a subset of patients experiencing a rapid disease course in the first two years and some developing disease transformation to a more aggressive phenotype. The advent of highly effective therapies has resulted in an increasing number of patients who achieve long-term progression-free survival alongside a good quality of life. Monoclonal antibodies, such as rituximab, either alone or in combination with chemotherapy regimens or radioimmunotherapy have been used with significant improvements in outcome. New treatment strategies such as new antibodies, biologic agents or vaccination therapy are also under investigation for the treatment of relapsed or refractory disease, further expanding the available options for patients and physicians alike. This article presents an overview of the current therapeutic strategies for the management of follicular lymphoma, focusing on the issues encountered in clinical practice.

Identificador

http://serval.unil.ch/?id=serval:BIB_A72B785FBEFE

isbn:1424-3997 (Electronic)

pmid:21815111

doi:10.4414/smw.2011.13247

isiid:000293596900001

http://my.unil.ch/serval/document/BIB_A72B785FBEFE.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_A72B785FBEFE0

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

Swiss Medical Weekly, vol. 141, pp. w13247

Tipo

info:eu-repo/semantics/review

article